risankizumab
abbvie
['ibd']
 tells us about the promising role for anti-il23 agents particularly in atnf experienced patients #aibd2022 
Gastroenterologist with focus on #IBD and quality improvement @utswnews (Tweets mine, not medical advice, of course)